Last Updated: May 7, 2026
IV Ketamine vs. At-Home Ketamine: Which Lasts Longer?
IV ketamine and at-home ketamine therapy use the same molecule but deliver meaningfully different treatment experiences and outcome trajectories. This article explains how each modality works, how long symptom relief typically lasts, and what the published clinical evidence shows about durability and long-term outcomes.
Key takeaways
- In a peer-reviewed study of 11,441 patients participating in at-home sublingual ketamine therapy, 61.4% achieved clinically significant improvement in depression scores by week four. Response rates grew from 42.3% at week two to 56.4% at week four across the multi-week protocol.
- Single-dose IV ketamine produces published 24-hour response rates of approximately 27 to 50% across randomized trials and meta-analyses.
- Among patients who achieved clinically significant change in an initial four-week course of at-home sublingual ketamine therapy, 84% maintained or recovered it during a second round of care.
- IV ketamine's antidepressant benefit from a single dose is largely undetectable by two weeks, and even after a series of infusions, symptom relapse occurs at high rates within the first month of treatment cessation.
What Is IV Ketamine Infusion Therapy?
Intravenous administration of sub-anesthetic ketamine takes place in a medical setting with a nurse or anesthetist present throughout the session. Ketamine has been FDA-approved as an anesthetic since 1970 and has been on the WHO List of Essential Medicines since 1985.1 Use for depression, anxiety, and PTSD represents off-label prescribing by licensed clinicians based on clinical judgment.11
Most published IV protocols involve a series of infusions administered over several weeks in a hospital or office. Each infusion typically lasts 40 to 60 minutes, followed by an additional clinical monitoring period before the patient is cleared to leave. The intravenous route provides near-complete bioavailability, meaning virtually all of the administered dose reaches the bloodstream. Patients cannot drive home and require a support person for transport.
IV ketamine is one of several established routes of administration with a substantial evidence base for rapid symptom relief. Its primary trade-offs are the higher cost, the time commitment per session, and the requirement to travel to a facility for every infusion.
| Feature | IV Ketamine | Sublingual At-Home | Subcutaneous At-Home | Spravato (esketamine) |
|---|---|---|---|---|
| Administration | Intravenous infusion | Oral tablet | Small injection | Nasal spray |
| Setting | Hospital or office | Home | Home | Certified REMS facility |
| Bioavailability | ~100% | ~25 to 35% | ~90%+ | ~48% |
| Monitoring | In-person staff | Peer treatment monitor | Peer treatment monitor | In-person staff |
| FDA Status | Approved anesthetic (off-label for mood) | Approved anesthetic (off-label for mood) | Approved anesthetic (off-label for mood) | Approved for TRD and MDSI |
| Relative Cost | Highest | Lowest | Lower than IV | Varies by insurance |
What Is Clinician-Guided At-Home Ketamine Therapy?
Clinician-guided at-home ketamine therapy involves sublingual tablets or subcutaneous injections self-administered in a patient's own home under remote clinical oversight. A designated peer treatment monitor is required to be present during every session to ensure safety and provide support.
Comprehensive programs begin with a provider consultation for clinical evaluation to determine whether at-home ketamine is clinically appropriate, followed by a defined number of sessions delivered over several weeks. Sublingual tablets are held between the cheek and gum, while subcutaneous injections are administered via a small insulin needle. Bioavailability is lower for sublingual medicine (25 to 35%) and higher for subcutaneous delivery (90%+). Provider-determined dosing accounts for these route differences to ensure appropriate care.
Each appointment is embedded in a broader therapeutic framework that includes preparation beforehand, the experience itself in a familiar environment with curated audio and an eye mask, and integration afterward. The at-home model is designed so that the therapeutic environment, integration support, and care programming work alongside the medicine. It is not simply IV ketamine minus the office visit. The familiar setting, the absence of post-session travel, and the ability to remain in a calm environment during the post-session transition window are intentional design features.
Core components of a supervised at-home protocol include:
- Clinical consultation: A licensed professional conducts a comprehensive evaluation, determines whether treatment is clinically appropriate, and establishes personalized dosing.
- Peer treatment monitor: A trusted adult is required to be present during every session for safety and grounding.
- Preparation and set/setting: Patients receive guided pre-session materials, curated soundscapes, an eye mask, and instructions for optimizing their comfortable home environment.
- Integration support: Post-session coaching, journaling, and reflection practices help translate the acute experience into lasting behavioral change.
Which Lasts Longer: IV Ketamine or At-Home Ketamine Therapy?
How long symptom relief lasts depends entirely on whether you are measuring the acute effects of a single dose or the durable benefit after a full course of treatment. Acute session effects describe how long you feel the medicine during and immediately after a single dose. Durable symptom relief measures how long the therapeutic benefit persists after a course of treatment.
IV ketamine has a documented advantage in speed of onset and single-dose response, but the decisive contrast lies in the treatment trajectory: IV response tends to peak early and decay, while at-home programs are designed to build and sustain response across a multi-week course.
How Long the Session Effects Last
Acute effects refer to the subjective and physiological experiences during and immediately after a single ketamine dose. These effects can include dissociation, perceptual changes, and altered mood. In supervised settings, the dissociative state is generally considered part of the therapeutic process rather than a side effect. Preparation materials and your peer treatment monitor are part of the protocol designed to help navigate the experience.
Duration varies by route of administration. IV infusion effects typically begin within minutes and resolve within one to two hours after the infusion ends. Sublingual effects begin within 10 to 15 minutes of administration and generally resolve within two to three hours. Subcutaneous effects begin in approximately five minutes.
Across all routes, most people feel back to baseline within a few hours, though some residual calm or fatigue may persist. Driving and operating machinery should be avoided until after a full night of sleep. Acute experience duration is not the same as therapeutic duration. A shorter or longer subjective experience does not predict whether symptom relief will last days, weeks, or months.
How Long Symptom Relief Lasts After IV Ketamine
Most IV ketamine studies track depressive symptom change using clinical scales like the HAM-D or MADRS after a single infusion or a short series of infusions. A single IV ketamine dose can produce rapid antidepressant effects. Published single-dose response rates within 24 hours range from approximately 27% in randomized double-blind trials2 to approximately 41% in pooled meta-analyses,10 with higher rates of 50 to 60% reported only after a series of repeated infusions over two weeks or more.2
However, the antidepressant benefit of a single IV dose is largely undetectable by two weeks. Within a series of infusions, the effect can be sustained or even strengthened during active treatment, but symptom relapse occurs at high rates within the first month after the series ends, with mean time to relapse reported at 18 to 19 days across studies of repeated thrice-weekly infusions.²,³,⁵
This post-cessation relapse pattern is not a failure of IV ketamine itself. It reflects the pharmacology of a single or short-series intervention delivered without a defined maintenance or post-experience processing framework. Because of this, many IV facilities recommend ongoing booster infusions, each requiring a return to the clinic for the full session and monitoring period.
How Long Symptom Relief Lasts After At-Home Ketamine Therapy
Published studies of clinician-guided at-home sublingual ketamine therapy track depressive symptom change via the PHQ-9 assessment across a structured multi-week course of sublingual ketamine therapy. Response is defined as a 50% or greater reduction in PHQ-9 scores, and remission is a score below 5. Clinically significant change requires a 5-point drop that crosses below the threshold of 10.
In the largest real-world study of any ketamine intervention published to date, an analysis of 11,441 patients receiving at-home sublingual ketamine therapy, response rates grew across the multi-week protocol. At week two, the response rate was 42.3%, with an 18.1% remission rate and a large effect size (Cohen's d = 1.15). By week four, the response rate grew to 56.4%, with 28.1% achieving remission and 61.4% achieving clinically significant change (Cohen's d = 1.46).⁶
Cross-study comparisons should be interpreted with appropriate context, since study designs, patient populations, and outcome measures differ across the trials. With those caveats, the published at-home sublingual response rates of 56% to 63% by the end of a four-week protocol match the response rates typically achieved with repeated IV ketamine infusion series. They also exceed the approximately 41% response rate reported in a meta-analysis of talk therapy for depression,⁸ and the approximately 40 to 50% response rates reported in SSRI antidepressant studies.⁹ Notably, these at-home effect sizes (Cohen's d = 1.46 to 1.61 across published cohorts) match or exceed the pooled effect sizes reported in IV ketamine meta-analyses, which is unusual for real-world data, since real-world effect sizes typically fall below those observed in controlled laboratory settings.
Critically, the reported response rate increased across the protocol rather than peaking early, which is the opposite trajectory from the IV peak-and-decay pattern. These published outcomes reflect results within a comprehensive program that includes medical oversight, preparation, and guided reflection. Individual results vary, and response is typically evaluated across a full course of treatment.
Why Durability May Differ Between the Two Modalities
One possible explanation for these different trajectories is that a multi-week at-home course produces a different durability curve than a facility-based infusion series, even though the active molecule is the same. Emerging evidence suggests several candidate explanations for the difference.
- Integration and behavioral reinforcement: At-home protocols that include preparation, guided sessions, and post-experience reflection create deliberate opportunities to translate acute neuroplastic effects into lasting cognitive and behavioral change. The session opens a therapeutic window, and integration is what builds through it.
- Environmental continuity and set/setting: The patient remains in a familiar, calm environment before, during, and after the session. There is no post-session travel, no car ride home while still in a dissociative state, and no transition from a medical to a home environment.
- Cumulative dosing within a defined treatment framework: A multi-week protocol with personalized treatment frequency may allow neuroplastic changes to compound across sessions. A short infusion series followed by cessation may not provide the same cumulative runway.
These concepts are hypotheses supported by emerging evidence, not established conclusions. In practice, durability likely depends on more than the molecule and route of administration alone.
Maintenance and Long-Term Outcomes
Maintenance in ketamine therapy refers to ongoing sessions after an initial treatment course, designed to sustain therapeutic gains and prevent symptom relapse. How maintenance is handled differs significantly between facility-based and at-home modalities. Long-term outcomes depend on more than just whether someone continues sessions. Reflective practices, lifestyle factors, and the quality of the therapeutic framework all contribute to sustained benefit.
Ongoing Maintenance Sessions for IV Ketamine
After an initial series, many IV facilities recommend periodic booster infusions to sustain the initial response. No field-wide standard governs the frequency or duration of maintenance infusions; some patients return monthly, others every few months.3
Each maintenance visit requires travel to the office, the full infusion and monitoring period, and a support person for transport home. Per-visit cost generally remains the same as the initial series. Published evidence supports the efficacy of weekly IV maintenance infusions in sustaining response among initial responders, though the time and travel commitment per visit remains the same as the initial course, since IV maintenance retains the full infusion and monitoring protocol regardless of how far into treatment the patient is.
Round 2 and Sustained Response After At-Home Protocols
Dosing frequency in an at-home model is personalized based on individual progress and clinical guidance. Mindbloom offers programs of 6, 12, or 18 sessions. After you select a program, a provider conducts the same comprehensive evaluation described above to personalize your care plan.
Among clients who achieved clinically significant change after their first round of treatment and elected a second four-week course, 84% either maintained that improvement or recovered it during the second round.⁶ This sustained-response cohort, drawn from a sample of over 1,200 patients, has no equivalent in the published IV ketamine literature, where the largest reported maintenance dataset tracked 23 responders through weekly clinic-based infusions. Put differently, the protocol-driven at-home model supports sustained and renewable benefit at a scale facility-based protocols have not matched in published research.
Not everyone needs a second round, and session frequency is adjusted over time based on progress and goals. The at-home model is designed to prioritize continuity and sustained engagement across the full treatment course.
Conclusion
IV ketamine excels at rapid single-dose relief, while supervised at-home protocols that include clinical oversight, preparation, and guided reflection are designed to build and sustain response across a multi-week course.
Neither modality is universally superior. Which path is best depends on individual needs, preferences, access, and the quality of the therapeutic framework. You should discuss both options with a licensed provider to determine the best path forward. Mindbloom provides one clinically managed at-home option backed by peer-reviewed outcomes data, offering a comprehensive care model designed for durable change.
Important Safety Information
Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information
Off-Label Use Disclosure
Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.
Frequently asked questions
Can You Switch from IV Ketamine to At-Home Ketamine and Keep Results?
Yes, many people transition between modalities based on changing needs, preferences, or access. A clinical evaluation is the appropriate first step to determine whether an at-home protocol is a good fit. Symptom relief is not locked to a single route of administration; what matters is the quality of the care protocol and support framework.
Do You Need Maintenance Sessions to Keep Ketamine Results?
Dosing frequency is personalized based on individual needs and clinical guidance. Some people sustain benefit after a single course with integration practices alone, while others benefit from additional appointments over time. A provider can help evaluate whether continued care is appropriate based on your symptom trajectory and individual goals.
What Should You Track to Tell If Ketamine Benefits Are Lasting?
Validated self-report tools like the PHQ-9 for depression and GAD-7 for anxiety are the same instruments used in clinical research and can help you and your provider monitor progress over time. Journaling about mood, sleep, energy, and daily functioning between appointments also provides useful signals regarding your symptom trajectory.
Is At-Home Ketamine Therapy Safe Without an IV Nurse?
In supervised ketamine care, clinicians monitor for known acute effects such as dissociation, transient increases in blood pressure, nausea, dizziness, and sedation, while serious adverse events are rare in appropriately screened patients. Safety is a function of clinical supervision, rigorous screening, and defined treatment frameworks rather than the physical presence of a nurse. In a peer-reviewed study of 11,441 at-home sublingual ketamine patients, serious adverse events occurred in fewer than 0.1 percent of patients (6 of 11,441).
How Does the Cost of IV Ketamine Compare to At-Home Programs?
Intravenous ketamine infusions are typically the most expensive route of administration due to the overhead costs of facilities and in-person staff. At-home ketamine therapy is generally more affordable because it utilizes telehealth and remote monitoring. Mindbloom programs are approximately 60 percent more affordable per session than average IV ketamine clinics. Mindbloom's at-home ketamine therapy ranges from $165 to $215 per session for new clients depending on program length, billed in monthly installments. The 18-session program starts at $165 per session, the 12-session program at $185, and the 6-session program at $215. Returning clients pay as little as $129 per session with an 18-session program.
Does Spravato Last Longer Than IV Ketamine?
Spravato is an FDA-approved esketamine nasal spray that requires administration and monitoring in a certified clinical setting. Like IV ketamine, it often requires an ongoing maintenance schedule to sustain therapeutic benefits over time. How long any ketamine therapy lasts depends heavily on the accompanying therapeutic framework and post-experience support.
Can You Drive After an At-Home Ketamine Session?
You must avoid driving or operating heavy machinery until after a full night of sleep following any ketamine dose. While the acute effects resolve within a few hours, the safety protocol ensures that any residual fatigue or mild cognitive changes have completely passed. Your monitor (described above) is present to assist during the transition back to baseline.
Mindbloom Treatment
See what might be possible with clinician-guided, at-home ketamine therapy. New client programs start at $165 per session.
Authors
